AMGN vs BMY
Amgen and Bristol Myers Squibb, both Healthcare
Amgen is the larger company at $182B against $110B. On trailing earnings BMY is the cheaper of the two at a P/E of 13.0 against 25.8, a gap that is only a bargain if the two are growing at similar rates. Over the past year AMGN returned +54% against +34% for BMY. The RyuScore puts AMGN ahead, 66 against 54 out of 100.
| Figure | AMGN | BMY |
|---|---|---|
| Last close | $415 | $59.11 |
| Market cap | $182B | $110B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 25.8 | 13.0 |
| Dividend yield | 2.4% | 4.2% |
| 1-year return | +54% | +34% |
| 5-year return | +122% | +14% |
| RyuScoresector-relative, 1–10 | 66/100 | 54/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
Bristol Myers Squibb
Revenue of $13B in Q2 2026, net income $3.3B. Its largest reported line is Eliquis, 33% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.